OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models
Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1941-1941
Open Access | Times Cited: 12
Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1941-1941
Open Access | Times Cited: 12
Showing 12 citing articles:
Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
Oncology Reports (2024) Vol. 52, Iss. 5
Open Access | Times Cited: 5
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
Oncology Reports (2024) Vol. 52, Iss. 5
Open Access | Times Cited: 5
Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH2Mab-250 in Human Breast Cancer Xenografts
Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1079-1079
Open Access
Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1079-1079
Open Access
Anti-HER2 cancer-specific mAb, H2Mab-250-hG<sub>1</sub> possesses higher complement-dependent cytotoxicity than trastuzumab
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
(2024)
Open Access | Times Cited: 3
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
(2024)
Open Access | Times Cited: 3
Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8386-8386
Open Access | Times Cited: 3
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8386-8386
Open Access | Times Cited: 3
Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9190-9190
Open Access | Times Cited: 3
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9190-9190
Open Access | Times Cited: 3
A Cancer-Specific Anti-Podoplanin Monoclonal Antibody, PMab-117-mG2a Exerts Antitumor Activities in Human Tumor Xenograft Models
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
Cells (2024) Vol. 13, Iss. 22, pp. 1833-1833
Open Access | Times Cited: 1
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
Cells (2024) Vol. 13, Iss. 22, pp. 1833-1833
Open Access | Times Cited: 1
Molecular Biology of Cancer—Interplay of Malignant Cells with Emerging Therapies
Stergios Boussios, Matin Sheriff, Saak V. Ovsepian
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 13090-13090
Open Access | Times Cited: 1
Stergios Boussios, Matin Sheriff, Saak V. Ovsepian
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 13090-13090
Open Access | Times Cited: 1
Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C44Mab-108) Using Enzyme-Linked Immunosorbent Assay
Hiroyuki Suzuki, Mayuki Tawara, Aoi Hirayama, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2024) Vol. 43, Iss. 3, pp. 85-89
Open Access
Hiroyuki Suzuki, Mayuki Tawara, Aoi Hirayama, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2024) Vol. 43, Iss. 3, pp. 85-89
Open Access
Defucosylated Anti-CD44 Monoclonal Antibodies Exert Antitumor Activities against Esophageal Tumor Xenograft
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
(2024)
Open Access
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
(2024)
Open Access
C<sub>8</sub>Mab-21: A Novel Anti-human CCR8 Monoclonal Antibody for Flow Cytometry
Tomohiro Tanaka, Hiroyuki Suzuki, Guanjie Li, et al.
(2024)
Open Access
Tomohiro Tanaka, Hiroyuki Suzuki, Guanjie Li, et al.
(2024)
Open Access
Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
(2024)
Open Access
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
(2024)
Open Access
Nimotuzumab and irinotecan synergistically induce ROS‐mediated apoptosis by endoplasmic reticulum stress and mitochondrial‐mediated pathway in cervical cancer
Fei Teng, Lujun Zhao
Biotechnology and Applied Biochemistry (2024)
Closed Access
Fei Teng, Lujun Zhao
Biotechnology and Applied Biochemistry (2024)
Closed Access
